Commercially available Inceptiv™ neurostimulation systems
DeviceSpinal cord stimulation therapy delivered during trialing and following implant of commercially available Inceptiv™ neurostimulation systems
NCT Number: NCT07507422
The PERSIST study is being conducted within Medtronic's active post-market surveillance platform, the Product Surveillance Registry (PSR). The purpose of PERSIST is to generate long-term evidence for the Inceptiv™ Spinal Cord Stimulation therapy.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Center for Pain and Supportive Care, Phoenix, Arizona, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients enrolled into the study with Diabetic Peripheral Neuropathy, Complex Regional Pain Syndrome and Upper Limb pain are required to meet further inclusion/exclusion criteria in order to contribute to the analysis for that particular condition. These criteria are designed to ensure that the patient's condition aligns with the standard diagnostic criteria set by applicable clinical guidelines.
Painful Diabetic Peripheral Neuropathy (DPN) Inclusion Criteria
Painful DPN Exclusion Criteria
Complex Regional Pain Syndrome (CRPS) Inclusion Criteria
CRPS Exclusion Criteria
Upper Limb Pain (ULP) - non CRPS Inclusion Criteria
ULP - non CRPS Exclusion Criteria
Spinal cord stimulation therapy delivered during trialing and following implant of commercially available Inceptiv™ neurostimulation systems
Time frame: Baseline and 6 months after device activation
This outcome measures the percentage of implanted patients who demonstrate improvement in pain for the predominant pain condition being treated at 6 months following device activation, compared to baseline. Pain is assessed using the NPRS (with 0=no pain and 10=highest level of pain).
Time frame: Baseline and 6 months after device activation
A composite responder is defined as an implanted patient who demonstrates an improvement from baseline in at least one of the following measures at the specified follow-up time: pain, quality of life, or pain-related disability.
Pain is assessed using the Numeric Pain Rating Scale (NPRS 0=no pain and 10=worst possible pain), with improvement defined as a reduction in pain score from baseline. Quality of life is assessed using the EQ-5D-5L index value, with improvement defined as positive change from baseline. Pain-related disability is assessed using the Pain Disability Index (PDI), with improvement defined as negative change from baseline.
Time frame: Baseline and 3 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months, 48 months, 54 months, 60 months after device activation
A composite responder is defined as an implanted patient who demonstrates an improvement from baseline in at least one of the following measures at the specified follow-up time: pain, quality of life, or pain-related disability. Pain is assessed using the Numeric Pain Rating Scale (NPRS 0=no pain and 10=worst possible pain), with improvement defined as a reduction in pain score from baseline. Quality of life is assessed using the EQ-5D-5L index value, with improvement defined as positive change from baseline. Pain-related disability is assessed using the Pain Disability Index (PDI), with improvement defined as negative change from baseline.
Contact information is provided by the study sponsor or research team.
Medtronic
Industry
Post Market Evaluation of Real World Outcomes and Durability to Support Implantable SCS Therapy (PERSIST) Addendum - Inceptiv™ Spinal Cord Stimulation (SCS) Therapy
Acronym: PERSIST
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07190807
Back Pain, Chronic Leg Pain
Greenwood, Colorado, United States
View Trial DetailsNCT04909593
Back Pain, Chronic Pain
Greenville, South Carolina, United States
View Trial DetailsNCT01854229
Back Pain, Cancer Pain
La Jolla, California, United States
View Trial DetailsNCT03082261
Chronic Pain, Intractable Pain
Phoenix, Arizona, United States
View Trial Details